| Product name | SSX Polyclonal Antibody |
| Immunogen | Synthesized peptide derived from the C-terminal region of human SSX |
| Host | Rabbit |
| Reactivity | Human |
| Applications | WB,IHC,IF,ELISA |
| Applications notes | Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000;IHC: 1:100-300;ELISA 1:20000;IF 1:50-200 |
| Clonality | Polyclonal |
| Preparation method | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Alternative | SSX1; Protein SSX1; Cancer/testis antigen 5.1; CT5.1; Synovial sarcoma, X breakpoint 1; SSX2; SSX2A; SSX2B; Protein SSX2; Cancer/testis antigen 5.2; CT5.2; Synovial sarcoma, X breakpoint 2; Tumor antigen HOM-MEL-40; SSX3; Protein SSX3; Cancer/testis antigen 5.3; CT5.3; SSX4; SSX4A; SSX4B; Protein SSX4; Cancer/testis antigen 5.4; CT5.4; SSX5; Protein SSX5; SSX6; Putative protein SSX6; SSX7; Protein SSX7; SSX8; Protein SSX8; SSX9; Protein SSX9 |
| Formulation | Liquid solution |
| Concentration | 1 mg/ml |
| Molecular weight | 25kD |
| Storage buffer | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage instructions | Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing. |
| Shipping | Gel pack with blue ice. |
| Precautions | The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product. |
| Background | The product of SSX1 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX2 and SSX4 family members, have been involved in t(X;18)(p11. ;q11. ) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome X. |
| Gene ID | 6756 |
| Alternative | SSX1; Protein SSX1; Cancer/testis antigen 5.1; CT5.1; Synovial sarcoma, X breakpoint 1; SSX2; SSX2A; SSX2B; Protein SSX2; Cancer/testis antigen 5.2; CT5.2; Synovial sarcoma, X breakpoint 2; Tumor antigen HOM-MEL-40; SSX3; Protein SSX3; Cancer/testis antigen 5.3; CT5.3; SSX4; SSX4A; SSX4B; Protein SSX4; Cancer/testis antigen 5.4; CT5.4; SSX5; Protein SSX5; SSX6; Putative protein SSX6; SSX7; Protein SSX7; SSX8; Protein SSX8; SSX9; Protein SSX9 |
| Others | SSX Polyclonal Antibody detects endogenous levels of SSX protein. |
| Accession | Q16384 |
| Observed Band(KD) | 25 |
Fig.1. Western Blot analysis of 22RV-1, SW480 cells using SSX Polyclonal Antibody. Secondary antibody (catalog#: A21020) was diluted at 1:20000.
Fig.2. Immunohistochemical analysis of paraffin-embedded human-skin, antibody was diluted at 1:100.
You must be logged in to post a review.
Reviews
There are no reviews yet.